RayKnowChina Research Map
Shortlist0

Not yet recruitingStomach cancerPhase 2

Registered title, quoted from ClinicalTrials.gov

Endoscopic Cryoablation Combined With PD-1 in Advanced Gastric Cancer

An open trial on stomach cancer, registered on ClinicalTrials.gov. Led by Huashan Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Huashan Hospital复旦大学附属华山医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT06759233, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to 80 years; sex: all

    Registered eligibility fields

  2. WHO pathology type: adenocarcinoma, neuroendocrine tumor;

    Inclusion criterion 3

  3. Patients diagnosed with advanced gastric cancer (stage IV in AJCC 8th edition staging, including locally progressive gastric cancer with unresectable factors (IVa) and gastric cancer with distant metastases (IVb); Bowman's staging type I, II, and III), who are unable to be surgically resected or do not tolerate surgical resection, and who have undergone progression after 1-2 lines of conventional chemotherapy;

    Inclusion criterion 1

  4. ECOG score ≤2;

    Inclusion criterion 9

  5. Important organ functions must be met: ① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula;

    Inclusion criterion 5

    Blood routine: Hgb≥70g/L,ANC≥1.5×109/L,PLT≥80×109/L;

    Inclusion criterion 6

  6. Pregnancy test must be negative in women of childbearing age;

    Inclusion criterion 8

    Pregnant or breastfeeding women, or women with pregnancy plans within six months;

    Exclusion criterion 1

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: earlier treatment; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT06759233, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Patients diagnosed with advanced gastric cancer (stage IV in AJCC 8th edition staging, including locally progressive gastric cancer with unresectable factors (IVa) and gastric cancer with distant metastases (IVb); Bowman's staging type I, II, and III), who are unable to be surgically resected or do not tolerate surgical resection, and who have undergone progression after 1-2 lines of conventional chemotherapy;
  • Age greater than 18 years and less than 80 years;
  • WHO pathology type: adenocarcinoma, neuroendocrine tumor;
  • Expected survival greater than 3 months and controllable distant metastases as judged by the physician;
  • Important organ functions must be met: ① Liver function: ALT and AST ≤ 2.5 times the positive range, total bilirubin ≤ 2.0mg/dL; ② Renal function: creatinine clearance ≥ 40mL/min calculated using the EPI formula;
  • Blood routine: Hgb≥70g/L,ANC≥1.5×109/L,PLT≥80×109/L;
  • Coagulation function: PT and APPT <2 times the normal value;
  • Pregnancy test must be negative in women of childbearing age;
  • ECOG score ≤2;
  • Signed informed consent.

Exclusion Criteria:

  • Pregnant or breastfeeding women, or women with pregnancy plans within six months;
  • Infectious diseases (e.g. AIDS, syphilis, active tuberculosis);
  • Patients with active hepatitis B or C infection;
  • Combination of other primary malignant tumors;
  • Patients who have participated in a clinical trial within one month;
  • Patients taking antiplatelet or anticoagulant drugs within the last week;
  • Patients with gastric cancer combined with active bleeding;
  • Large amount of ascites (ascites ≥3000ml);
  • Cardia obstruction or pyloric obstruction;
  • patients with combined active infection or autoimmune disease;
  • Those who the doctor thinks there are other reasons not to be included in the treatment.

Quoted from ClinicalTrials.gov, NCT06759233, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT06759233, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT06759233